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Tiivistelmä 
Hiilihappoanhydraasi IX (CA IX) on solukalvoentsyymi, joka katalysoi hiilidioksidin 
hydraatiota. Se auttaa ylläpitämään syöpäsolujen kasvulle ja elinvoimaisuudelle 
edullisia pH-olosuhteita. CA IX on merkkiproteiini hypoksialle, minkä taas on 
huomattu olevan huonon selviytymisennusteen indikaattori tietyissä syöpätyypeissä. 
Vaikka CA IX:ää on analysoitu intensiivisesti viime vuosikymmenien aikana, niin osa 
sen biokemiallisista ominaisuuksista oli vielä selvittämättä silloin, kun tämä tutkimus 
tehtiin. Tästä syystä tämän työn tarkoituksena oli tuottaa ja puhdistaa CA IX -
rekombinanttiproteiinineja hyönteissoluissa käyttäen bakulovirusekspressiosysteemiä. 
Tämä oli ensimmäisiä tutkimuksia, joissa hiilihappoanhydraaseja tuotettiin 
hyönteissoluissa. Tarkoitus oli käyttää tuotettuja CA IX -proteiineja 
aktiivisuusmäärityksiin ja muihin tutkimuksiin biokemiallisten ominaisuuksien 
määrittämiseksi. CA IX:n katalyyttinen domeeni ja proteoglykaanidomeeni tuotettiin 
erikseen, puhdistettiin ja analysoitiin. Lisäksi tutkittiin myös CA IX:ää, jossa oli 
kummatkin domeenit samassa rekombinanttiproteiinissa. Käytetyn 
hyönteissolutuottosysteemin todettiin olevan toimiva tapa tuottaa CA IX:ää. Havaittiin, 
että proteoglykaanidomeeni nostaa CA IX entsyymin aktiivisuutta. Lisäksi 
aktiivisuusarvot vahvistivat aikaisemmat tutkimukset, joiden perusteella CA IX:n 
katalyyttisen domeenin  aktiivisuus on keskitasoa. Kuitenkin havaittiin, että ZnCl2 
lisäysreaktioon lisäsi huomattavasti CA IX:n katalyyttistä aktiivisuutta ja sen todettiin 
olevan CA IX:n erityisominaisuus. Aktiivisuusarvot, jotka mitattiin kokopitkälle CA 
IX:n muodolle ZnCl2:n läsnäollessa, olivat korkeimmat, mitä oli koskaan mitattu 
hiilihappoanhydraaseilla.  
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Abstract 
Carbonic anhydrase IX (CA IX) is a cell surface enzyme, which catalyzes CO2 
hydration. It has a function to maintain favorable pH conditions for cancer cell growth 
and survival. Expression of CA IX is a marker of hypoxia, which has been noticed to be 
an indicator for poor prognosis in specific cancers. CA IX has been analyzed intensively 
during the last decades but some of its biochemical properties were not revealed until 
this study was conducted. Hence, the recombinant protein forms of CA IX were 
produced and purified in this study using the baculovirus insect cell expression system. 
The aim was to produce CA IX recombinant proteins for further studies to analyze the 
activity and other biochemical properties of these enzymes. The recombinant proteins, 
which had either the catalytic domain or the proteoglycan domain of CA IX were 
separately produced, purified and analyzed. Additionally a CA IX form having both 
domains in the same recombinant protein was also studied. The used baculovirus insect 
cell expression system was found to be a feasible way to produce recombinant CA IX. It 
was found that the proteoglycan domain has a notable influence on enzyme activity of 
CA IX. In addition, activity values confirmed the previously reported results that the 
catalytic domain of CA IX has average activity as compared to the other CA isozymes. 
However, the addition of ZnCl2 to the reaction was found to increase the catalytic 
activity of CA IX, and this property was concluded to be a unique feature for CA IX. In 
the presence of ZnCl2 the catalytic activity of the full-length recombinant protein having 
both the catalytic and proteoglycan domains was higher than measured before for any 
other CAs. 
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   carbonic	  anhydrase	  IX	  CA9	  CA	  XII	  CA	  XIV	  CA	  XV	  
carbonic	  anhydrase	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1 Introduction 
Carbonic anhydrase IX (CA IX) is a cell surface enzyme, which belongs to a larger α-
CA gene family and is strongly associated to malignant tumors (Pastorekova, Zavada 
2004, Syrjanen, Luukkaala et al. 2014). Expression of CA IX is a marker of hypoxia, 
which has been noticed to be an indicator for poor prognosis in specific cancers (Potter, 
Harris 2003, McDonald, Winum et al. 2012). The function of CA IX has been linked to 
maintain favorable pH conditions for cancer cell growth and survival. It creates 
acidification at cell surface and disrupts cell-to-cell interactions increasing tumor 
propagation (Svastova, Zilka et al. 2003, Swietach, Hulikova et al. 2010). Due to these 
properties and because the expression of CA IX is mainly limited to tumor cells 
(Pastorekova, Zavada 2004), CA IX is an important target molecule in cancer therapy 
and diagnostics (Pastorekova, Parkkila et al. 2006, McDonald, Winum et al. 2012). 
Clinical trials in diagnostic purposes have yielded positive results and additionally 
promising results have been reported in cancer therapy studies conducted with 
monoclonal antibodies and small molecule inhibitors (McDonald, Winum et al. 2012).  
In order to analyze the properties and functions of CA IX in detail, it was necessary to 
produce CA IX as a recombinant protein for these studies. 
 
Recombinant proteins can be produced by various expression systems, such as chemical 
synthesis or bacterial, fungal, insect and mammalian cells (Kollewe, Vilcinskas 2013). 
Bacteria are usually the first option considered when the longer peptides or complete 
proteins are aimed to be produced. Bacterial cells are used because high amounts of 
recombinant proteins can be generated in relatively short time and little effort 
(Structural Genomics, China Structural Genomics et al. 2008). However, in this study a 
eukaryotic expression system was chosen for recombinant CA IX production. This is 
because bacterial cells (E. Coli) had been already used in CA IX recombinant protein 
production and because CA IX has post-translational modifications, which are not 
produced correctly in bacterial cells. 
 
Insect cell expression systems represent a rational compromise between the bacterial 
and the mammalian expression systems (Becker-Pauly, Stöcker 2011). In insect cells, 
signal peptides are cleaved as in mammalian cells, disulfide bonds can be formed and 
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proteolytic processing is possible because of protein-converting enzymes (Jacobs, 
Callewaert 2009).  In addition, larger amounts of the recombinant proteins are possible 
to be produced especially when insect cells are cultured in suspension cultures (Jarvis 
2009). The aim was to produce high amounts of recombinant proteins in this study 
because of aimed crystallization experiments and other studies.  
 
Even though CA IX has been studied widely, some of its biochemical properties were 
still unknown at the time when this study was conducted. At that time recombinant CA 
protein production had not been tested in insect cells. Therefore, the aim of this study 
was to produce and purify recombinant proteins, which could be used in activity studies 
and in further analyses, such as inhibitory and oligomerisation studies as well as 
crystallization experiments to define the 3D structure of CA IX.  
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2 Review of the literature 
2.1 α-Carbonic anhydrases 
Carbonic anhydrases are ubiquitous metallo-enzymes in the nature, which usually 
contain a zinc atom as a metal cofactor. They are found in animals, plants and also in 
microbes. CAs exist in different forms, with different structures, in different molecular 
weights and also their activities vary. These enzymes are involved in basic cellular 
processes, such as photosynthesis, respiration, transportation of ions, calcification, and 
regulation of acid–base balance. Additionally, CAs are the fastest known enzymes. 
There are five different CA families (α, β, γ, δ and ζ) (Kanth, Pack 2013). Human 
CA IX, which is the target enzyme in this study, belongs to the α-CA gene family 
(Pastorekova, Zavada 2004).  
 
α-carbonic anhydrases participate in several functions in human metabolism, such as  
respiration, bone resorption, production of gastric acid and different body fluids, renal 
and testicular acidification, and other biological processes (Pastorekova, Zavada 2004). 
In the regulation of acid base balance, α-CAs use zinc-activated hydroxide mechanism 
to catalyze the conversion of carbon dioxide and water to bicarbonate and proton in a 
reversible reaction (CO2 + H2O ↔ HCO3- + H+) (Supuran, Scozzafava 2007). α-CAs 
are expressed in several locations in the cell. CA I-III, CA VII and CA XIII are 
expressed in the cytosol. CA IV, CA IX, CA XII and CA XIV are located on the cell 
surface. CA VA and CA VB are proteins found in mitochondria and CA VI is a secreted 
protein. All these CA isozymes are catalytically active in mammals. The decreased 
activity of certain isozymes has been associated with several diseases including 
glaucoma, osteopetrosis, heart oedema, renal failure, and neurological and 
neuromuscular disorders, etc. (Pastorekova, Zavada 2004). The connection with cancer 
was, however, not noticed before the discovery of CA IX (Pastorekova, Zavadova et al. 
1992).  
 
2.2 Carbonic anhydrase IX 
2.2.1 History  
CA IX was first found in HeLa-cells and at that time it was named as MN-protein 
(Pastorekova, Zavadova et al. 1992). Later, when the cDNA of the MN-protein was 
managed to be cloned, it was noticed that the MN-protein had strong homology with α-
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CA family (Pastorek, Pastorekova et al. 1994).  Because of this strong homology and 
enzyme activity, MN-protein was named to CA IX. However, Oosterwijk et al had 
noticed even earlier that the antibody G250 recognized an antigen in kidney cancer cells 
(Oosterwijk, Ruiter et al. 1986). Years later, this particular antigen was identified to be 
CA IX (Grabmaier, Vissers et al. 2000). 
 
2.2.2 Molecular properties  
2.2.2.1 Gene transcription  
CA IX is located in chromosome 9p12-p13 (Nakagawa, Uemura et al. 1998). The 
coding sequence of the gene is split to 11 exons and the size of the protein is 10.9 kb 
(Opavsky, Pastorekova et al. 1996). The mRNA is transcribed as a size of 1,5kb and on 
reducing conditions SDS-PAGE, CA IX migrates as 54kDa and 58 kDa double bands. 
(Pastorek, Pastorekova et al. 1994).  
 
There are no found mutations in the CA9 cDNA, which could possible cause different 
functions between normal and cancer cells (Pastorekova, Parkkila et al. 1997). 
However, by using RT-PCR (real-time polymerase chain reaction), an alternative 
mRNA splicing variant of CA9, that does not include exons 8-9, has been found. This 
alternative form of the mRNA is expressed in very low concentrations in several 
different cell lines, and it is coding a shorter and less active form of the mRNA of the 
CA IX protein.  The physiological role of this alternatively spliced variant has not yet 
been identified, but it is indicated that the splicing variant may functionally intervene 
with the full-length CA IX. This could be relevant especially under the conditions of a 
mild hypoxia (Barathova, Takacova et al. 2008).  
 
2.2.2.2 Structure 
CA IX is a glycoprotein that is located at the cell surface. CA IX migrates as a 153-kDa 
band on non-reducing conditions in SDS-PAGE, which was the reason why CA IX was 
assumed to be a trimeric protein (Pastorekova, Zavadova et al. 1992). This trimeric 
structure is stabilized by the formation of intermolecular disulfide bonds mediated by 
cysteine residues. There are three histidine residues on the bottom of the catalytic center 
of CA IX and they bind a one zinc ion. CA IX has a signal peptide, a catalytic domain, a 
proteoglycan-like domain, a transmembrane region, and a cytoplasmic tail 
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(Pastorekova, Zavada 2004). The organization of the domains of CA IX is demonstrated 
in a Figure 1. 
  
Figure 1. The domain organization of CA IX: SP (a signal peptide), PG (a 
proteoglycan-like domain), CA (a catalytic domain), TM (a transmembrane region) and 
IC (a cytoplasmic tail). The figure is modified from original reference (Pastorekova, 
Zavada 2004) 
 
2.2.3 Expression and connection to prognosis 
CA IX is expressed only in a few normal tissues. It has been identified for example, in 
gastric mucosa and gall bladder by immunohistochemical staining (Pastorekova, 
Parkkila et al. 1997). Smaller amounts have also been found in intestinal epithelia, 
pancreatic duct, and testis (Ivanov, Liao et al. 2001).  
 
A special characteristic property of the CA IX expression is that it is overexpressed 
especially in cancer tissues, whereas its expression in normal tissues is usually very 
low. In addition, the expression of CA IX in malignant tissues is connected to poor 
prognosis (Potter, Harris 2003, Maseide, Kandel et al. 2004, Driessen, Landuyt et al. 
2006, McDonald, Winum et al. 2012). According to the literature review conducted by 
Christian Potter and Adrian L Harris, the expression of CA IX correlated with poor 
prognosis in breast, lung, cervical, head and a neck cancer (Potter, Harris 2003). Also in 
stomach and oesophagus cancer, the expression of CA IX has been linked to poor 
prognosis (Driessen, Landuyt 2006). Additionally, tissue microarray studies have 
supported the correlation between the expression of CA IX and poor survival in breast, 
lung, ovarian and bladder cancers as well as in astrocytomas (McDonald, Winum et al. 
2012).  
 
CA IX expression does not, however, always correlate with poor prognosis. According 
to Nakamura et al, the expression of hypoxia inducible factor-1 (HIF-1α) correlated 
significantly with poor survival of stomach cancer patients, whereas correlation with the 
CA IX expression was not found (Nakamura, Kitajima et al. 2011). The weak 
expression of CA IX in kidney cancer was connected to poor survival and strong 
expression was connected to better prognosis (Bui, Visapaa et al. 2004).  Also 
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according to the literature review made by Stillebroer et al,, the strong homogenic 
expression of CA IX in kidney cancer is related to a better response to systemic 
treatment and survival (Stillebroer, Mulders et al. 2010).  
 
2.2.4 Regulation of gene expression  
2.2.4.1 Effect of hypoxia and acidosis on regulation of CA IX expression  
Hypoxia is particularly related to cancer tissues. It induces transcription factors, which 
further activate several different genes. These activations will lead to a cell response 
that usually causes growth and proliferation of the cancer cells. For this reason, hypoxia 
has an important role in tumorigenesis, tumor development and metastasis (Brahimi-
Horn, Pouyssegur 2007).  
 
CA IX is usually expressed strongly in cancer tissues in hypoxic conditions. In a 
hypoxic environment, a hypoxia responsive element (HRE) has an effect on the 
expression of CA IX through HIF-pathway (Wykoff, Beasley et al. 2000). The HRE 
activates gene transcription of CA IX in the hypoxic environment. The HRE is activated 
by a transcription factor HIF1 (hypoxia inducible factor-1) that consists of two sub-
units, HIF1α and HIF1β. HIF1α stabilizes in hypoxic conditions, and after that it 
drifts into a nucleus. In the nucleus, HIF1β is expressed constantly and after HIF1α 
has drifted into the nucleus HIF1α  and HIF1β  together will form an active 
transcription factor HIF1 (Pastorekova, Ratcliffe et al. 2008).   
 
In normal conditions, the HRE-gene expression is prevented when a von Hippel Linday 
(VHL) tumor suppressor ubiquitin-protein binds to the hydroxylated HIF1α sub-unit 
and forms an ubiquitin system. This will lead to fragmentation of the ubiquitin complex 
and consequently, drifting of the HIF1α into the nucleus will be prevented (Semenza 
2001). The loss of function in VHL in renal cell carcinomas and cerebellar 
hemangioblastomas cancer causes constant HIF1 α -activation, which finally leads to 
the overexpression of CA IX (Semenza 2001, Supuran 2008). 
 
Protected regions PR1 - PR5 affect also the regulation of CA IX expression. In the 
circumstances when HIF1 is active, the SP1/SP3 transcription factors bind on PR1- and 
PR5-protected regions. This phenomenon has been found to be critical for the CA IX 
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transcription. This influence for CA IX transcription has been indicated by using SP1 
inhibitor (Mithramycin A), which has been noticed to prevent expression of CA IX 
(Kaluzova, Pastorekova et al. 2001, Kaluz, Kaluzova et al. 2003). Activation protein 1 
has also an important role in activation of CA IX transcription and it binds to the 
position PR2 (Laderoute 2005). The PR3 region binds also proteins that have been 
noticed to have positive effect on activation of CA IX promoter, but the functions of 
these proteins are still unknown. Region of PR4 have been conversely perceived to act 
as a silencer in transcription of CA IX (Kaluz, Kaluzova et al. 1999).  
 
Acidosis, which is prevalent in a microenvironment of high cell density tissues, has 
been noticed to have an effect to regulation of CA IX expression. Acidosis as well as 
PI-3K (phosphatidylinositol 3-kinase) has a stabilizing influence on HIF-1α, which 
enhances drifting of the HIF-1α into the nucleus (Kaluz, Kaluzova et al. 2009).  
Regulation of CA IX expression is visualized in Figure 2.  
 
Figure 2. Regulation of CA IX expression. The figure is modified from original 
references (Kaluz, Kaluzova et al. 2009, De Simone, Supuran 2010)  
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2.2.4.2 Effects of methylation status on regulation of the CA IX expression  
In the region of CA9 gene promoter, methylation of CpG sites has been detected to have 
an important function in the regulation of gene expression. Especially, methylation 
status at -74 and -6 CpG sites have been correlated with CA IX expression in kidney 
cancer cells. Ashida et al noticed that all studied CA IX positive cell lines were hypo-
methylated (decreased methylation) and all CA IX negative cell lines were hyper-
methylated (increased methylation) (Ashida, Nishimori et al. 2002).  
 
Also Grabmaier et al showed that CA IX expression and hypo-methylation of the CA 
IX promoter correlates in the kidney cancer. In addition, they noticed that hypo-
methylation did not occur in primary kidney cancer cells or in normal kidney tissues. 
Additionally they identified that re-cultured primary kidney cancer cells had increased 
hypo methylation status in a CA IX gene. Because hypo-methylation was only detected 
in cultured kidney cells, except primary kidney cancer cells, Grabmaier et al assumed 
that hypo methylation of CA IX promoter was induced by in vitro-conditions in tissue 
cultures (Grabmaier, de Weijert et al. 2002).  
 
Jakubickova et al investigated the methylation of the CA IX promoter using HeLa 
cervical carcinoma cells. The study showed that the methylation of CA IX promoter 
decreased the expression of CA IX in dense cell cultures but it did not occur in hypoxia 
or in sparse culturing conditions. Therefore it was concluded that the methylation of CA 
IX promoter may not be an essential factor in HeLa cervical carcinoma cells in gene 
regulation of CA IX, but it could be an additional mechanism in the regulation of CA 
IX promoter in dense cell cultures. (Jakubickova, Biesova et al. 2005). 
 
As mentioned before, hypoxic environment has been detected to have a strong influence 
on the CA IX expression. However, CA IX expression and hypoxia are not always 
correlating and the regulation mechanisms of CA IX are still partially unknown. For 
example, Nakamura et al have showed that the regulation of CA IX is more depended 
on methylation status than the stimulation caused by hypoxia. According to 
immunohistochemical studies, the epigenetic changes in CA IX differ in a diffuse-type 
stomach cancer and an intestine cancer. In the diffuse-type stomach cancer, the 
increased methylation rates have been identified and in the intestine cancer the 
decreased methylation rates have been observed (Nakamura, Kitajima et al. 2011).  
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2.2.5 Function  
2.2.5.1 Catalytic activity 
Similarly to other α-CAs, one function of CA IX is to act in the zinc-activated 
hydroxide mechanism to catalyze carbon dioxide in a reversible reaction, forming 
hydrogen carbonate. (Supuran, Scozzafava 2007). In the active site of CA IX there is a 
zinc ion coordinated by three histidine residues, which has important function for the 
catalytic activity of CA IX (Pastorekova, Zavada 2004).  
 
The hydroxide ion is bound to the zinc ion on the active (basic) form of an enzyme. 
When the carbon dioxide bounds to a hydrophobic pocket, it will react in a reversible 
reaction with a zink coordinated hydroxide ion, forming a bicarbonate-ion. When a 
water molecule replaces the bicarbonate-ion, the result will be the formation of an 
inactive (acidic) form of the enzyme. In order to transform back to the catalytically 
active form, a proton transfer reaction from the active site to the surroundings will 
occur. This reaction is essential for the reaction rate, and it is presumably assisted by 
histidine residue of the active site (Supuran, Scozzafava 2007). These catalytic reactions 
have been presented in reaction formulas a) and b). In the reaction formula a) and b), E 
refers to enzyme (Supuran, Scozzafava 2007). 
 
a) EZn2+- OH- + CO2 ⇔ EZn2+- HCO3-  ⇔ H2O EZn2+- OH2 + HCO3- 
b) EZn2+ - OH2 ⇔ EZn2+ - HO- + H+   
 
 
2.2.5.2 Effect on pH control 
CA IX is usually expressed in highly differentiated and metabolically active cells, such 
as cancer cells. Therefore, CA IX has been suggested to have an essential physiological 
function in the regulation of pH-balance in tumor tissues (Swietach, Hulikova et al. 
2010). CA IX actively increases the acidification of the cell surface and it neutralizes 
the intra cellular pH, protecting cancer cells from hypoxia and acidosis (Swietach, 
Hulikova et al. 2010, Svastova, Hulikova et al. 2004).  
 
CA IX is assumed to co-operate with anion exchangers in the pH-balance regulation. 
When CA IX converts carbon dioxide to hydrogen carbonate, anion exchangers in the 
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cell surface will use the hydrogen carbonate. In that case the hydrogen carbonate is 
transported through these anion exchangers to the cytosol and in the cytosol CA II will 
transform the hydrogen carbonate back to carbon dioxide, which then diffuses out of the 
cell. (Pastorekova, Zavada 2004).  
 
Morgan et al have also studied the interactions of CA IX with anion exchangers. They 
assumed that Clˉ/HCOˉ₃ -exchangers (anion exchangers AE1, AE2 ja AE3) interact 
physically as well as functionally with CA IX. The assumption was that CA IX and 
anion exchangers could form together a bicarbonate transport metabolon system 
(Morgan, Pastorekova et al. 2007). Even though this direct binding of CA IX and anion 
exchangers has been questioned, co-operation of CA IX with anion exchangers is 
considered to be possible (Swietach, Hulikova et al. 2010, Boron 2010). Also the study 
by Svastova et al supports an assumption of the interaction of CA IX with anion 
exchangers and as well as the formation of the metabolon system of CA IX with anion 
exchangers (Svastova, Witarski et al. 2012). 
 
The glucose metabolism of healthy normal cells usually uses a mitochondrial pathway, 
whereas cancer cells prefer a glycolytic route, which leads to high lactic acid 
concentrations (Brahimi-Horn, Pouyssegur 2007). As mentioned previously, CA IX has 
been noticed to function actively, neutralizing the pH of the cytosol in these acidic 
conditions. Swietach et al have suggested that CA IX may use three different 
mechanisms when participating in the pH balance regulation. In oxidation conditions, 
catalysis may occur using a mitochondrial model and in glycolytic environment (cancer 
cells), depending on expression and activity of the anion exchangers, using either an  
HCOˉ₃ titration model or an H⁷ extrusion model (Swietach, Hulikova et al. 2010). CA 
IX catalyzes carbon dioxide to hydrogen carbonate in the mitochondrial model and in 
the titration model. In these cases, extra cellular pH will decrease and intra cellular pH 
will increase. Instead, in the extrusion model the extra cellular pH will increase and the 
intra cellular will decrease. The HCOˉ₃ titration model corresponds the hypoxic 
environment of the tumor cells when dehydration of CA IX will neutralize intra-cellular 
pH, enhancing tumor growth. (Swietach, Hulikova et al. 2010, Svastova, Hulikova et al. 
2004). Svastova et al have also showed experimentally how the protons of CA IX may 
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cause acidosis in hypoxic conditions in the microenvironment of tumors.  (Svastova, 
Hulikova et al. 2004).  
 
2.2.5.3 Effect on adhesion, migration and proliferation of the cells 
CA IX has a proteoglycan-like domain, which indicates that it may be related to cell 
adhesion (Zavada, Zavadova et al. 2000). Typical properties of cancer tissues include 
strong cell division and migration. It has been noticed that CA IX increases the de-
adhesion of cells and thus induces tumor progression (Svastova, Zilka et al. 2003). 
 
Svastova et al have indicated that CA IX may negatively affect E-cadherin-mediated 
cell adhesion over β-catenin. The E-cadherin is an important adhesion molecule whose 
disappearance or instability is linked to tumor progression. Because of this connection, 
the disruptive effect of CA IX to E-cadherin-mediated cell-adhesion and strong 
expression of CA IX in the malignant tissues can be assumed to be connected to each 
other (Svastova, Zilka et al. 2003).  
 
According to Hulikova et al, also the intracellular tail has been detected to have an 
influence on the de-adhesion of CA IX expressing cells.  Hulikova et al found that 
mutations in the basic amino acids of the intracellular tail did not disrupt the 
localization of CA IX on cell membrane, but decreased CA IX-mediated de-adhesion of 
the cells (Hulikova, Zatovicova et al. 2009).  
 
2.2.6 Clinical significance   
2.2.6.1 In diagnosis 
CA IX is a potential marker of cancer, because it is very strongly expressed in cancer 
tissues, but the expression in normal tissues is low (Potter, Harris 2003). Antibodies 
M75 and G250 recognize the CA IX protein. The M75 is a very specific antibody for 
the PG-domain of CA IX and it is generally used to identify CA IX in 
immunohistochemical studies. However, for the radiolabeling and for the immune 
therapy an alternative antibody, chimeric antibody cG250, has been developed 
(McDonald, Winum et al. 2012).  
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Divgin et al analyzed 25 patients who were suspected to have kidney cancer, using 
iodine-124-labelled antibody chimeric G250 Positron-Emission Tomography (124) I-
cG250 immuno-PET). Sixteen of the studied patients were assured to have kidney 
cancer, and in fifteen of those patients, cancer was also identified in (124) I-cG250 
PET-scanning. (124) I-cG250 binding was not detected in any of the patients who did 
not have kidney cancer. The study showed that (124) I-cG250 PET could be a feasible 
way to diagnose malignant tumors and a potential method in decreasing invasive 
surgeries (Divgi, Pandit-Taskar et al. 2007). The expression in kidney cancer has also 
been observed in a preclinical study (mouse model) using Immuno-Pet ((89) Zr- cG250 
immuno-PET) where the signal was clearly positive in kidney tumors (Stillebroer, 
Mulders et al. 2010).  
  
2.2.6.2 In cancer therapy 
CA IX is a possible target also in the cancer therapy. One method is to use CA IX-
specific monoclonal antibodies (mAbs) in immune therapy. It is possible to achieve 
therapeutic influence via several different mechanisms by using these monoclonal 
antibodies. For instance, a direct binding of these monoclonal antibodies may cause a 
toxic cell response, which could have an inhibitory effect on the tumor. Alternatively, 
antibodies can be used to direct various therapeutic molecules such as cytotoxines or 
radionuclides on the cell surface (McDonald, Winum et al. 2012). 
 
Another method in CA IX-mediated cancer therapy is to use CA IX-specific small 
molecule inhibitors. Several different molecules and compounds are known to 
effectively inhibit CAs. Especially sulfonamides, sulfomates and coumarines have been 
noticed to have an inhibitory effect on malignant tumors. The sulfonamides inhibit the 
function of CA IX by binding to the zinc ion on the active site of CA IX, whereas 
coumarine and thiocoumarine bind to a gap of the active site, thus inhibiting the enzyme 
activity. Several studies have been conducted to analyze the effects of the inhibitors. 
Results have been mostly positive when studying the effects of inhibitors to the tumor 
progression (McDonald, Winum et al. 2012).  
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2.3  Recombinant protein production  
2.3.1 Chemical synthesis  
It is possible to produce short linear peptides using a purely chemical synthesis. Proteins 
produced by chemical synthesis are also easier to purify than those produced by other 
expression systems, due to the less complex production conditions. The chemical 
synthesis has, however, limitations, such as restricted amino acid length, and difficulties 
to produce peptides containing high proportion of challenging amino acids, such as 
arginine, cysteine, methionine and tryptophan. Also post-translational modifications are 
a challenging issue when using chemical synthesis (Kollewe, Vilcinskas 2013). Besides 
the challenges in the synthesis of peptides containing post-translational modifications, 
the peptides containing disulfide bonds have been synthesized (Reinwarth, Nasu et al. 
2012). 
 
2.3.2 Bacterial cells 
Bacteria are usually the first option to be considered when longer peptides or complete 
proteins are produced, because high amounts of the recombinant proteins can be 
generated in relatively short time and little effort (Structural Genomics, China Structural 
Genomics et al. 2008). Most commonly used bacteria are gram-negative Escherichia 
coli (E.coli) and gram-positive Bacillus subtilis (B.subtilis). Bacillus subtilis is mostly 
used in industrial applications (Westers, Westers et al. 2004, Rosano, Ceccarelli 2014). 
However, in spite of the extensive knowledge in the molecular biology of bacteria, the 
recombinant protein production in bacteria may also be challenging (Sivashanmugam, 
Murray et al. 2009). For instance, some issues may appear in the expression of the 
genes with unique structural features, translational efficiency, and stability of mRNA. 
Additional challenges may appear especially with protein folding and other post-
translational modifications. There might also be problems with protein degradation by 
host cell proteases, and with protein being toxic to the host cells (Sivashanmugam, 
Murray et al. 2009). Some of these problems can be solved by suitable design of 
expression systems, such as by selecting a correct host strain, plasmid, and promoter. 
The ideal promoter for the expression of recombinant proteins in E. coli directs efficient 
transcription and protein production, which is tightly regulated to minimize metabolic 
burdens and toxic effects. In addition, the process of mRNA degradation provides a 
major control point of gene expression. Also codon optimization may be essential, if the 
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sequence of the produced protein contains non-typical codons for E.coli (Jana, Deb 
2005). 
 
If the structure or function of the recombinant protein depends on disulfide bonds, 
proteolytic cleavage, or other post-translational modifications, bacteria may not be the 
ideal production system. The targeting of recombinant proteins into the periplasmic 
space can encourage the formation of disulfide bonds, but amounts of the produced 
recombinant protein tends to be significantly lower in contrast to cytoplasmic 
expression (Mergulhao, Summers et al. 2005). Under these circumstances, a eukaryotic 
expression system could be a more functional option.  
 
2.3.3 Yeast cells 
Yeasts have been popular hosts for recombinant protein production in industrial 
applications, because these expression systems are economical, they can rapidly reach 
high cell densities and high protein concentrations, and they do not contain pathogens or 
viral inclusions (Celik, Calik 2012). In addition, yeast cells have an ability to perform 
better eukaryotic post-translational modifications when compared to bacteria 
(Mattanovich, Branduardi et al. 2012). However, proteins with antifungal activity are 
difficult to produce in yeast cells and the glycosylation in yeast differs from human 
cells. This may lead to hyperglycosylation, which may reduce enzyme activity or make 
the protein immunogenic (Jayaraj, Smooker 2009).  
 
There are plenty of yeast expression hosts, such as Saccharomyces cerevisiae, Pichia 
pastoris, Hansenula polymorpha, Kluyveromyces lactis, Schizosaccharomyces 
pombe, Yarrowia lipolytica, and Arxula adeninivorans (Celik, Calik 2012). Two of the 
most used yeast strains are S. cerevisiae and the methylotrophic yeast P. Pastoris 
(Demain, Vaishnav 2009). Saccharomyces cerevisiae is the first and best characterized 
yeast expression system. A wide variety of recombinant proteins produced in S. 
cerevisiae have been listed in a review made by Demain and Vaishnav. The 
recombinant proteins manufactured in S. cerevisiae are, for instance, insulin, hepatitis B 
surface antigen, urate oxidase, glucagon, granulocyte macrophage colony stimulating 
factor, hirudin, and platelet-derived growth factor (Demain, Vaishnav 2009). However, 
numerous cases of plasmid instability, low protein yields, and the hyperglycosylation of 
the proteins have limited the use of S. Cerevisiae (Celik, Calik 2012). 
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An advantage of P.Pastoris, when compared to other yeasts, in manufacturing 
recombinant proteins is its ability to secrete proteins. Success has been achieved in 
genetically engineered P. Pastoris secretory pathway in order to produce human type N-
glycosylated proteins (Choi, Bobrowicz et al. 2003). P. Pastoris has several advantages 
over S. Cerevisiae as a cloning host, such as higher protein productivity as well as lack 
of hyperglycosylation. It can be cultured in methanol solutions, and it is economical to 
set up and maintain. In addition, integration of multiple copies of foreign DNA into 
chromosomal DNA yields stable transformants. There are, however, some 
disadvantages when using P. Pastoris as a host for heterologous expression. A number 
of proteins require chaperones for proper folding, and P. Pastoris is unable to produce 
such proteins (Demain, Vaishnav 2009).  
 
2.3.4 Insect cells 
Insect cell expression systems are a considerable compromise between bacterial and 
mammalian expression systems (Becker-Pauly, Stöcker 2011). In insect cells, the signal 
peptides are cleaved as in mammalian cells, disulfide bonds are formed in the 
endoplasmic reticulum, and protein-converting enzymes are available for proteolytic 
processing (Jacobs, Callewaert 2009).  
 
The insect cell lines used in recombinant protein production usually achieve higher cell 
densities than mammalian cells.  Thus smaller culture volumes are needed. All in all, 
the insect cell cultures are less demanding than mammalian cells. With insect cell 
cultures, shake or spinner flasks can be used, and there is no need for a CO2 atmosphere 
because insect cell culture media are buffered with phosphate (Moraes, Jorge et al. 
2012, Jarvis 2009). However, the sterility of the cell culture conditions is equally 
important. In contrast to mammalian cell cultures, the biosafety level is not increased 
when a heterologous gene is introduced by baculovirus infection. Although the insect 
cell expression systems are an effective and functional way to produce recombinant 
proteins, the bacterial expression system may be a preferable option if the recombinant 
protein does not require post-translational modifications (Kollewe, Vilcinskas 2013).  
 
There are several insect cell expression systems available, such as stably transfected 
drosophila cells, stably-transfected lepidopteran cell lines, site-specific gene integration 
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for stable expression, and baculovirus expression vector system (BEVS) (Kollewe, 
Vilcinskas 2013). The most commonly used vector system for recombinant protein 
expression in insect cells is the baculovirus (Demain, Vaishnav 2009).  
 
2.3.5 Mammalian cells 
Mammalian cells are well suited for demanding proteins when, for instance, glycan 
structures or other post-translational modifications are critical for the protein structure 
(Kim, Kim et al. 2012). Chinese hamster ovary cells (CHO) are particularly widely used 
for the production of recombinant proteins (Zhu 2012). The fast way to produce 
recombinant proteins in mammalian cells is transient transfection (Baldi, Hacker et al. 
2007). Transient transfection is, however, more suitable for analytical experiments than 
in large-scale production, because it is not sufficiently productive. Because of the low 
yields of the recombinant proteins with transient transfection, especially in CHO cells, 
an alternative strategy is to use a stable transfection. The stable transfection allows the 
selection of individual high-yielding cells to increase overall productivity (Ye, Alvin et 
al. 2010). In addition, CHO cells have been also indicated as safe hosts, and thus it is 
easier to obtain approval to the market from regulatory agencies such as the FDA (Kim, 
Kim et al. 2012). In mammalian cells, viruses can also be used for transfection. Then 
the produced protein yields may be higher, but when viruses are used, the biosafety 
level is higher which will increase expenses of the protein production (Kollewe, 
Vilcinskas 2013).  
 
2.4 Insect cell expression systems 
2.4.1 Stably-transfected drosophila cells 
Drosophila Schneider cells were isolated from late-stage Drosophila melanogaster 
embryos over 30 years ago (Schneider 1972). Drosophila Schneider cells are still used. 
However, to date only Schneider's cell lines 2 and 3 are used for heterologous gene 
expression. Drosophila S2 cells are suitable for high-level, low-cost production of 
eukaryotic proteins. It is possible to integrate multiple copies of expression plasmids 
allowing isolation of highly productive and stable polyclonal cell lines. S2 cell cultures 
may achieve high cell densities, which can also decrease laboratory expenses (Moraes, 
Jorge et al. 2012). Additionally they can be maintained at room temperature in serum-
free media without CO2 supply. Endogenous Drosophila proteins generally do not 
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interact with mammalian proteins. Therefore S2 cells can provide a “null background” 
for functional studies of the proteins (Invitrogen). Drosophila S2 cells can also produce 
recombinant proteins with post-translational modifications, such as glycan structures 
(Becker-Pauly, Stöcker 2011). However, in some cases the molecular weight of the 
protein has been different compared to the native mammalian protein.  Some differences 
have also been detected in glycosylations, but despite differences in the structure, the 
activity of the protein has been even higher (Li, Tsing et al. 1996, Chang, Yang et al. 
2005) 
 
There are several factors that affect the growth and gene expression of S2 cells: 
particularly the selected cell line, cell passage, inoculum concentration, culture medium, 
temperature, dissolved oxygen concentration, pH, hydrodynamic forces, and toxic 
metabolites (Moraes, Jorge et al. 2012). In spite of the fact that S2 cell lines are difficult 
to grow at low densities, which somehow limits the process to select the desired cell 
clone, good performances in terms of the desired heterologous protein production have 
been reported (Lemos, Santos et al. 2009, Dos Santos, Lemos et al. 2009, Ventini, 
Astray et al. 2010, Yang, Song et al. 2012). 
 
2.4.2 Stably-transfected lepidopteran cell lines 
Genetically transformed lepidopteran insect cell lines have biotechnological 
applications as constitutive recombinant protein production platforms, and as improved 
hosts for baculovirus-mediated recombinant protein production (Lin, Jarvis 2013). 
Although Sf9 and High FiveTM cells are generally associated with the baculovirus 
expression vector system, they are also used for stable transfection (Gouveia, Kandzia 
et al. 2010). Constitutive expression is generated by means of Immediate Early (IE) 
promoters from Multicapsid Nuclear Polyhedrosis Viruses (MNPV) (Lin, Jarvis 2013). 
Stably transfected cells are selected using either a resistance gene cassette linked on the 
expression vector or unlinked on a separate plasmid. The protein amounts obtained are 
typically in the range of 0.2- 50 mg L−1 by using the commercially available 
InsectSelectTM System, by Life Technologies (Gouveia, Kandzia et al. 2010). 
 
2.4.3 Site-specific gene integration for stable expression 
Site-specific DNA integration allows heterologous gene expression without extensive 
clone screening (Fernandes, Vidigal et al. 2012). The site-specific DNA integration 
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technology has been used in cultured insect cells (sf9) and also in cultured mammalian 
cells. Additionally it is also used in organisms, such as drosophila and mice (Fernandes, 
Vidigal et al. 2012). 
 
A tagging cassette harboring a reporter gene is randomly introduced into the cell 
genome after screening different transfection protocols. After single-cell cloning, 
reporter gene expression is used to screen for high-producer clones. By using the 
Recombinase-Mediated Cassette Exchange (RMCE), any gene of interest can then be 
integrated into the first cell line genome at the same site. The cells are transfected with 
two plasmids, with the plasmid carrying the transgene flanked by compatible 
recombinase recognition sites and a plasmid providing the recombinase coding 
sequence. This recombinase coding sequence allows the transgene to be exchanged for 
an  integrated reporter gene (Turan, Zehe et al. 2013).  
 
2.5 Baculovirus expression vector systems (BEVS) 
Baculovirus–insect cell expression systems have the capacity to produce recombinant 
proteins at high levels by simultaneously providing protein-processing capabilities with 
high similarity to eukaryotic protein processing (Jarvis 2009).  Additionally BEVS is 
suitable for production of multi-protein complexes. BEVS can also provide specialized 
proteins for enhanced processing (e.g., chaperones) (Sokolenko, George et al. 2012). 
  
Through genetic manipulation baculoviruses, and in particular autographa californica 
multiple nucleopolyhedrovirus (AcMNPV), have been engineered to be a 
biotechnological tool that is able to transduce insect and also mammalian cells 
(Sokolenko, George et al. 2012). Gene transfer in the BEVS is carried out by a 
baculovirus infection, followed by episomal replication and expression, which remove 
the need to select integrated transgenes. In addition, strong viral promoters will help 
achieve high yields in recombinant protein production (Kollewe, Vilcinskas 2013).  
 
The first recombinant baculovirus vectors were produced using a homologous 
recombination. The double crossover recombination needed in this method was a 
relatively rare event. Additionally recognizing polyhedron-negative baculoviral plaques 
was a serious problem because it had to be done with a trained eye by visually 
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identifying polyhedron-negative plaques by examining the assay plate under a 
dissecting microscope (Jarvis 2009).  Since this first method to produce recombinant 
baculoviruses, more improved techniques have been developed. Improvements and 
modifications were made to transfer plasmids into the baculovirus genome.  
Commercialized examples of these techniques used in baculovirus expression system 
are, for instance, Bac-to-BacTM system by Life Technologies, flashBACTM by Oxford 
Expression Technologies, BaculoDirectTM system by Harwood and colleagues at 
Invitrogen and DiamondBacTM (Jarvis 2009).  
 
Because a Bac-to-BacTM system was used in this study, the method is described in more 
detail. In the Bac-to-Bac® Baculovirus Expression System, a gene of interest is first 
cloned into a donor plasmid (pFastBacTM). After the cloning, the correct sequence is 
checked by a restriction analysis, PCR or sequencing, or a combination of previous 
techniques. The confirmed donor plasmid is then transformed into competent cells (E. 
Coli DH10BacTM), which contain bacmid DNA, and a helper plasmid. After 
transposition, the bacmid is propagated in E. Coli DH10BacTM (Luckow, Lee et al. 
1993). The bacmid propagates in E. coli DH10BacTM cells as a large plasmid that 
confers resistance to kanamycin and can complement a lacZ deletion present on the 
chromosome to form colonies that are blue (Lac+) in the presence of a chromogenic 
substrate such as Bluo-gal or X-gal and the inducer, IPTG. Transposing a mini Tn7 
element from a pFastBacTM donor plasmid to the mini-attTn7 attachment site on the 
bacmid generates recombinant bacmids. A helper plasmid provides Tn7 transposition 
functions allowing the transfer of gene of interest into the bacmid DNA and it also 
confers resistance to tetracycline.  The resulting large molecular weight recombinant 
bacmid DNA can then be extracted and after PCR or sequencing confirmation of 
insertion, it may be transfected into insect cells to generate recombinant baculovirus. 
Once the virus is harvested and the titer checked by plaque assay, virus stocks can be 
grown and protein production assayed. As the system uses suspension cells, protein 
production can be scaled up as required (Bac-to-Bac® Baculovirus Expression System 
manual, Invitrogen).  
 
Another important part of the baculovirus expression system are the used insect cell 
lines. Most commonly used hosts for the baculovirus transfer vector are two 
lepidopteran insect cell lines Spodoptera frugiperda 9 (Sf9) and High FiveTM insect cells 
	   27	  
(Jarvis 2009). The Order Lepidoptera moths and butterflies are the hosts for many 
viruses in the family of Baculoviridae, including AcMNPV (Jarvis 2009). The first 
Lepidoptera insect cell cultures were established by Grace in 1962 (Grace 1962). 
Currently approximately 250 insect cell lines have been developed (Lynn 2007). Sf9 is a 
subclone of IPLB-SF-21 and it was described by Summers and Smith in 1987 
(Summers, Smith 1987). This cell line has been isolated from pupal ovarian tissue of 
Spodoptera frugiperda (fall armyworm) (Vaughn, Goodwin et al. 1977). The High 
FiveTM (BTI Tn 5B-1) cell line has been originally isolated from adult ovarian tissue of 
Trichoplusia ni (cabbage looper) in 1992 (Wickham, Davis et al. 1992).  
 
Sf9 and High FiveTM cells can be cultured in either adherent or suspension cultures. 
When the cells are cultured in suspension, the production can be scaled up as mentioned 
before. Adherent cultures are usually used for plaque assay and for quantify 
recombinant baculovirus expression vectors (Jarvis 2009). The optimal cell culture 
temperature is lower (28°C) for insect cells than for mammalian cell cultures (37°C). In 
addition, EDTA or trypsin is not needed because Sf9 and High FiveTM cells are not very 
adherent cells. Both cell lines can be cultured in either growth media with serum or in 
serum-free media. However, Sf9 and High FiveTM cells have to be adapted to a specific 
growth medium. It is advisable to do the adaptation by slowly weaning the cells out of 
the serum-containing medium into the serum-free medium. Sometimes the slow 
weaning is also needed to move insect cell cultures from one specific type of serum-free 
medium into another (Jarvis 2009). 
 
As mentioned earlier, in insect cells, recombinant proteins can be folded, they can be 
chemically modified and assembled into soluble end products. However, despite these 
properties, insect cell production systems have also limitations (Jacobs, Callewaert 
2009). For instance, both Sf9 and High FiveTM cells are inable to process N-linked 
carbohydrate side chains (N-glycans) to the same extent as in mammalian cells (Shi, 
Jarvis 2007).  While native mammalian glycoproteins often have complex N-glycan 
structures with terminal sialic acids, insect cell derived recombinant glycoproteins 
usually have much more simple side chains. These side chains are known as 
paucimannosidic N-glycans. In addition, insect-derived N-glycans may cause allergenic 
reactions. This may be a problem when the baculovirus insect cell expression system is 
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used for producing pharmaceutical applications, particularly in therapeutic applications 
(Shi, Jarvis 2007).  
 
Several strategies have been developed to solve this problem. For example, 
development of culture conditions that might support the production of recombinant 
glycoproteins with more authentic, mammalian-like N-glycans, and identifying 
alternative, natural baculovirus-host combinations that might be able to produce 
recombinant glycoproteins with more authentic N-glycans (Shi, Jarvis 2007). In 
addition, baculovirus vectors or their hosts have been genetically engineered to encode 
and express mammalian genes involved in the latter steps of N-glycan processing 
(Hollister, Jarvis 2001). 
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3 Aim of the study 
The aim of this study was to produce and purify recombinant CA IX enzymes using 
Bac-To-Bac baculovirus expression vector system in insect cells. Purifications were 
performed by using a His tag purification system and an Avidin tag purification system. 
Two different purification systems were used in order to find out which was more 
feasible for CA IX protein. The His tag was included either in C-terminus or in N-
terminus of the recombinant protein, in order to find out for which one of the His tags 
the thrombin cleavage would be more successful, and to find out if the His tag location 
has an effect on the enzyme activity. The work included the production and purification 
of CA IX catalytic domain and the proteoglycan domain. The catalytic domain and PG-
domain were produced separately, because the crystallization of the proteins was 
predicted to work better in two parts. The analysis of the enzyme activity of the 
catalytic domain was also studied. Enzymes and results produced in this thesis were 
aimed to be used in further studies that revealed biochemical properties of CA IX, such 
as oligomerisation, glycosylation and the 3D structure. 
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4 Materials and methods 
4.1 Recombinant protein production using Baculovirus expression system 
(BVES) 
Recombinant baculoviruses were manufactured according to the instructions of the Bac-
To-Bac® Baculovirus expression system (Invitrogen, Carlsbad, CA). 
 
4.1.1 Generation of the recombinant CA9 cDNA constructs 
Three cDNA constructs encoding the active domain of the human CA9 and one 
encoding the proteoglycan domain of the human CA9 were made using the stepwise 
elongation of sequence-PCR (SES-PCR). DNA and amino acid sequences of the 
produced proteins in the study are presented in Appendix 1. CA IX sequence was based 
on UniProt entry Q16790. The aim was to produce soluble recombinant proteins CAIX-
Chis, CAIX-NHis and CAIX-PG that could be purified directly from the insect cell 
medium. CAIX-Avd was aimed to be purified from the cells after sonication. Therefore 
the recombinant proteins CAIX-C-his, CAIX-N-His and CAIX-PG contained a CA9 
native signal sequence, of which codons had been optimized for the Spodoptera 
frugiperda 9 (sf9). CAIX-C-His, CAIX-N-His and CAIX-Avd included only the CA 
domain and CAIX-PG included only the PG-domain. CAIX-Avd contained the Avidin 
signal sequence and the Avidin linker. The transmembrane domain and the 
intracytoplasmic tail were removed from all the recombinant sequences in order to 
make secretion possible.  Sequences encoded also eight histidine residues (CAIX-C-
His, CAIX-N-His and CAIX-PG) or alternatively Avidin tag (CAIX-Avd) for protein 
purifications. A thrombin cleavage site was added for polyhistidine- and Avidin tag 
removal. BglII and HindIII restriction enzyme sites were included for cloning the 5´and 
3´ends, respectively.  cDNA constructs are presented in Figure 3. 
 
The PCR reactions were performed by using a thermal cycler (Gene Amp PCR system 
9700, Applied Biosystems, Foster City, CA). The enzyme used in these reactions was 
Phusion polymerase (Finnzymes, Espoo, Finland), and it was used according to 
manufacture´s instructions. 10 % dimethyl sulfoxide (DMSO) was used as an additive 
in PCR reactions C, D, E, G and J (Table 1), as in these reactions primer dimers due to 
long primer sequences interfered with the PCR reaction. Primer sequences used in SES-
PCR reactions are presented in Table 2. In the first PCR reaction, the template was the 
	   31	  
full-length human CA9 cDNA in the pOTB7 vector (IMAGE Clone 4865275, 
Geneservice Ltd, Cambridge, UK). PCR program for the first reaction (CAIX-PCR) 
included 98°C denaturation step for 2 minutes, which was followed by 33 cycles of 
denaturation at 98°C for 10 s, then annealing at 65°C for 30 s and extension at 72°C for 
one minute, followed by final extension at 72°C for 8 min.  With other reactions 
denaturation step was 3 minutes and extension time was 30 seconds followed by 7 
minutes final extension. Used temperatures were same with the exception of annealing 
temperatures mentioned in Table 1.  All PCR reactions are presented in Table 1.  
 
The PCR-products were analyzed using 1 % agarose gel electrophoresis containing 0,1 
µg/ml ethidium bromide and 100 bp DNA ladder (New England BioLabs, Beverly, 
MA). The gel running time was 35 minutes and voltage was 110V (Biometra, 
Göttingen, Germany). Correct PCR product was cut from the gel and purifications of 
the DNA were performed using GFX PCR DNA and Gel Band Purification Kit 
(Amersham Biosciences, Poole UK) according to manufactures instructions. The 
purified DNA was used as a template in further reactions as described in Table 1. 
 
 
 
      Figure 3. Schematic figure of the used CA IX cDNA constructs.  
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Table 1. SES-PCR reactions. 
Protein Reaction Template Primers Annealing T 
(°C) 
DMSO  
(5µ l) 
CAIX CAIX-PCR Vector F1+ R1 65 - 
CAIX-C-His A Vector F2+ R2 50 - 
 B CAIX-PCR F3+ R3 50 - 
 C B F3+ R4 50 + 
 D A+C F2+ R4 50 + 
CAIX-N-His E Vector F2+ R5 50 + 
 F CAIX-PCR F4+ R6 50 - 
 G E+F F2+ R6 45 + 
CAIX-Avd H CAIX-PCR F5+ R6 50 - 
 I H+ AVD F6+ R6 45 - 
CAIX-PG J Vector F2+ R7 45 + 
 
 
Table 2. Primer sequences used in the SES-PCR reactions (F=forward, R=reverse). 
Primers Sequences (5´à  3´) 
F1 CTGCTGCTTCTGATGCCTGTCC 
F2  GGCCAGATCTATGGCTCCCCTGTGCCCCTCCCCCTGGCTGCCCCTGCTGATCCCCGCTCCC 
F3  CACCCCCAGAGTCATTGGCGCTATGGAGGC 
F4  CCACAGGGACAAAGAAGGGGATGACCAGAGTCATTGGCGCTATGGAGGCGACCCGCC 
F5  GGTGGCTCCCTGGTGCCCCGTGGTTCCCACAGGGACAAAGAAGGGGATGACCAGAGT 
F6  GGCCAGATCTATGGTGCACGCAACCTCCCCG 
R1 CCTCTGGCTGGCTTCTCACATTCT 
R2  ATAGCGCCAATGACTCTGGGGGTGCACGGGCATCAGCAGCAGCAGGGA 
R3  ATGGTGGTGGGAACCACGGGGCACCAGAGGGAAGGAGGCCTCAATCACTCGCCCATT 
R4  TTCGCCAAGCTTTTAGTGGTGATGGTGGTGATGGTGGTGGGAACCACGGGGCACCAG 
R5  TGGTCATCCCCTTCTTTGTCCCTGTGGGAACCACGGGGCACCAGGTGGTGATGGTGG 
R6  TTCGCCAAGCTTTTAGAAGGAGGCCTCAATCACTCGCCCATT 
R7  TTCGCCAAGCTTTTAAGGTAGATCCTCTAACTTCAGGGAGCC 
 
4.1.2 Generation of the recombinant plasmid  
Enzymes BglII and HindIII were used to digest final PCR products and BamHI and 
HindIII were used to digest pFastBac1 vector. Ligation of the PCR products into the 
pFastBac1 vector was carried out using T4 ligase (Invitrogen). After ligation, the 
recombinant plasmids were transformed into TOP 10 cells according to manufacturer’s 
instructions (Invitrogen). Plasmids were purified using the Qiagen Spin Miniprep Kit 
(Hilden, Germany).  
 
Following the transformation and the purification, the plasmids were sequenced to 
confirm the correct coding sequence of the recombinant proteins. Sequencing was 
performed in both directions by means of ABI PRISM Genetic Analyser 9100 
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instrument (Applied Biosystems) and using the ABI PRISM Big Dye Terminator Cycle 
Sequencing ready Reactions Kit version 3.1 (Applied Biosystems). The reaction 
mixture contained 2 µl Bigdye mix, 2 µl sequencing buffer, 1 µl primer (1,6 pmol) 1 µl 
plasmid and 4 µl H2O and the PCR program was performed according to the 
instructions of the manufacturer. The ethanol precipitation was carried out in the 
following way: 80 µl of 76 % EtOH was added into sample tubes. This was followed by 
vortexing and incubation at room temperature for 15 minutes. After the incubation, the 
samples were briefly centrifuged and the supernatants were removed. Then 250 µl of 70 
% EtOH was added into the sample tubes and samples were mixed by vortexing and 
centrifuged for 10 minutes. After centrifugation, the supernatants were removed and 
samples were allowed to dry over night at 4°C. Next day the samples were re-suspensed 
with 13 µl Hidi and then mixed by vortexing. This was followed by fast spinning and 
incubation at 95°C for two minutes. Then the samples were put on ice and after that 
vortexing and spinning were conducted and finally the samples were kept on ice until 
placing them to the analyzer.  
 
4.1.3 Generation of the recombinant bacmid 
Site-directed transposition was used to generate recombinant bacmids containing the 
cDNAs coding for CA IX. In transposition, the DH10BacTM E. coli cells were used as a 
host for pFastBac1 vector. DH10BacTM cells contained a baculovirus shuttle vector 
(bacmid) and a helper plasmid. The helper plasmid contained Tn7 transposition 
functions that are needed for transposition with donor vector. The following method 
was used for transformation: a streak of DH10Bac bacteria was re-suspended to 100 µl 
of 100 mM CaCl2 and then incubated on ice for 15 min. After the incubation, 100 ng of 
plasmids were added to the cell suspension and incubation on ice continued 30 min. 
Heat shock was carried out at 37°C for 2 min and after heat shock 450 µl of SOC 
medium (Invitrogen) was added. The cells were grown for 4 hours in an orbital shaker 
at 37°C and then collected by centrifuging 1 minute at 6000g at 20°C.  After 
centrifugation, the cells were re-suspended to 100 µl SOC medium and then applied on 
Luria-Bertani (LB) plates that were prepared according to the Bac-to-Bac® instructions. 
Also the recombinant bacmid selection and transfection of the insect cells were 
performed according to the manufacturer’s instructions. 
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4.1.4 Production and purifications of the recombinant enzymes 
The Sf9 insect cells (Spodoptera frugiperda 9, Invitrogen) were cultured in HyQ SFX-
Insect serum free cell culture medium (Hyclone, Logan, UT) at 27°C in an orbital 
shaker. After 72 hours from infection, the culture medium was collected for protein 
purifications by centrifuging cells at 20°C, 5 minutes and 2000 G.  
 
The purifications for recombinant enzymes CAIX-C-His, CAIX-N-His and CAIX-PG 
were carried out using Probond™ Purification System (Invitrogen). The purifications 
were performed in the following way: 100 ml insect cell culture medium, 1000 ml of 
native binding buffer and 7 ml of the nickel-chelating resin were combined and then 
mixed on a magnetic stirrer at 25°C for 1 hour. During the time on the magnetic stirrer, 
His tagged proteins had possibility to bind to the resin. After mixing the resin and the 
insect cell culture medium on magnetic stirrer, the solution was transferred into the 
column. The resin was washed with 500 ml of binding buffer and the proteins were 
eluted with elution buffer containing 250 mM imidazole. The native binding, washing 
and elution buffers were prepared according to manufacturer´s instructions.  
 
Purifications for recombinant enzyme CAIX-Avd were performed using the Avidin-
biotin purification system. Avidin is a chicken egg-white glycoprotein, which can bind 
biotin molecules and therefore it is widely used for affinity-based separations (Airenne, 
Laitinen et al. 1999).  Purifications for CAIX-Avd were carried out as follows. The cell 
pellet (from 50 ml cell culture) was re-suspended to 10 ml Hillo I buffer (50 mM Tris–
HCl, pH 8/1% Triton X-100/2mM EDTA/150 mM NaCl) and then the suspension was 
sonicated for 4 minutes (pulse 5 second on and 1 off, amplitude 20 %) and centrifuged 
15000 G at 4°C for 15 minutes. During the centrifugation 2-iminobiotin-sepharose resin 
was prepared by washing (centrifugation 500 G for 5 minutes) it two times with 50 ml 
pH 11 buffer (50 mM Na2CO3, 1 M NaCl). After the 15 minutes centrifugation, 600 µl 
2-iminobiotin-sepharose resin was added into the supernatant and 15 ml tube was filled 
up with pH 11 buffer (binding buffer). After gentle shaking on a rotator at 4°C for 1 
hour, the resin was collected by centrifugation 500 G at 4°C for 5 minutes. Washing of 
the resin was carried out for two times with 15 ml binding buffer by centrifugation and 
the protein was eluted using pH 4 elution buffer (50 mM C2H3NaO2, 0,1M NaCl). 
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The purified CAIX-C-His and CAIX-N-His (CAIX-PG and CAIX-Avd were not 
managed to be purified) were exchanged into 50 mM Tris-HCl, pH 7.5 (Sigma-Aldrich, 
St. Louis, MO) by means of Amicon Ultra 10 kDa cut-off centrifugal filter devices 
(Millipore, Carrigtwohill, Ireland). Because of His tag removal, purified recombinant 
proteins were treated with 60 µl of 50 % thrombin slurry (Thrombin CleanCleave KIT, 
Sigma-Aldrich) per 1mg of protein with slow mixing on a rotator at 25°C for 1 hours. A 
filtration was used to remove the thrombin slurry from the protein solution and a 
centrifugal filter device was used to wash and remove the His tag. Even though long 
incubation times and high enzyme concentrations were tested, the His tag could not be 
removed from the CAIX-C-His. 
 
4.2 Characterization of the recombinant enzymes 
SDS-PAGE analyses were used to characterize recombinant enzymes. SDS-PAGE gels 
were treated with the Colloidal blue staining Kit (Invitrogen) or Western blotting. SDS-
PAGE gels were made from 5 % stacking and 10 % separating polyacrylamide gel and 
running of the gel was performed under reducing conditions according to previous 
literature (Laemmli 1970). Precision Plus Protein™ Dual Color Standard (Bio-Rad, 
Hercules, CA) was used for determining the molecular weight of proteins.  
 
Western blot analyses were performed using a Novex XCell II blot module (Invitrogen). 
The separated recombinant proteins were transferred electrophoretically from the gel to 
polyvinydine fluoride (PVDF) membrane (Macherey-Nagel, Düren, Germany) at 36 V 
and for 1 hour and 15 minutes. The proteins were blocked for 25 minutes with cow 
colostral whey (Biotop Oy, Oulu, Finland) diluted to 1:10 in TBST buffer (20 mM Tris, 
500 mM NaCl, 0.3 % Tween-20, pH 7.5). Then the proteins were incubated with 
primary antibody in TBST buffer for 60 minutes (His-mouse diluted 1:1000 for his tag 
and Avd-rabbit diluted 1:1000 for Avd tag). The antibody M75 diluted 1:100 was used 
to detect CAIX-PG (Pastorekova, Zavadova et al. 1992). After incubation, the 
membranes were washed 5 times for 5 minutes in TBST buffer. The secondary antibody 
(Horseradish peroxidase-labeled sheep anti-mouse IgG for M75) was diluted 1:25000 in 
TBST buffer and the membranes were incubated in secondary antibody for 60 minutes.  
After the incubation in the secondary antibody, the membranes were washed four times 
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for five minutes in TBST buffer. The ECL detection was completed according to 
manufacturer’s instructions (Amersham Biosciences).  
 
4.3 Protein concentration assays  
Concentrations of the purified recombinant proteins were measured using BCA Protein 
Assay Reagent Kit (Pierce, Rockfort, IL) and DC Protein Assay (Bio-Rad, Hercules, 
CA). The protocols were performed according to manufacturer´s instructions. 
Concentrations were measured using three different dilutions and X replicates. The 
mean values of these results were used as the final concentrations.  
 
4.4 Protein activity analyses 
Activity analyses were performed using an applied photophysics stopped-flow 
instrument in the laboratory of Dr. Claudiu T. Supuran (Bioinorganic Chemistry 
Laboratory, University of Florence, Italy). These analyses are reported in an article by 
Hilvo et al (Hilvo, Baranauskiene et al. 2008). 
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5 Results 
5.1 Production of recombinant proteins 
CA IX recombinant proteins were produced using Bac-To-Bac® Baculovirus 
expression system (Invitrogen, Carlsbad, CA) and Sf9 insect cells.  
5.1.1 PCR-products of the constructs 
PCR products encoding the recombinant proteins were separated and analyzed using 
agarose gel electrophoresis. The DNA ladder had 12 bands ranging from 100 to 1517 
base pairs. The 500 and 1000 base pair bands had increased intensity to indicate 
reference point. The lengths of the final DNA constructs were 940 bp (CAIX-C-His), 
970 bp (CAIX-N-His), 1300 bp (CAIX-Avd) and 420 bp (CAIX-PG). Several PCR-
reactions and DNA purifications were done before the final PCR-products, but those 
results are not shown. Complete digested PCR-products of the constructs are presented 
in Figures 4-6. 
 
 
Figure 4. 1. (CAIX-Avd) 
             2. (ladder) 
 
 
 
Figure 5. 1. (CAIX-C-His) 2. (-) 
       3. (ladder) 
 
 
Figure 6. 1. (CAIX-N-His) 2. (CAIX-PG) 
                                      3. (ladder) 
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5.1.2 Sequencing of the cDNA constructs 
Correct coding sequences of the recombinant proteins were confirmed by sequencing. 
Sequencing was performed in both directions. If the sequencing was successful in one 
or the other direction, the sequence was interpreted to be correct. Results of the 
sequencing are presented in appendix 2. 
 
5.1.3 Western Blot after production in insect cells 
Western Blot analysis was used to confirm that the insect cell medium contained correct 
produced recombinant proteins. Western Blot results are presented in Figures 7 and 8. 
Recombinant proteins CAIX-N-His, CAIX-C-His were detected from the insect cell 
medium using a primary antibody for the His tag (Figure 7). CAIX-Avd was detected 
using a primary antibody for the Avidin and the CAIX-PG were detected using a 
primary antibody for the PG-domain. CAIX-Avd and CAIX-PG were detected from 
insect cells after sonication (Figure 8). The standard that was used contained ten bands 
of molecular weights (10–250 kD) including eight blue-stained bands and two pink 
reference bands (25 and 75 kD). Molecular weights of the produced proteins were 
CAIX-C-His (34,8 kD), CAIX-N-His (35,9 kD), CAIX-Avd (48,1 kD) and CAIX-PG 
(15,5 kD). All produced proteins showed signals of correct molecular weights in 
Western Blot analyses.  
 
 
Figure 7. Western Blot analysis to the 
CAIX-N-His and the CAIX-C-His from 
culture medium of sf9 cells and from 
CAIX-Avd after sonication of sf9 cells. 
 
Figure 8. Western Blot from the CAIX-
PG-domain after sonication of the sf9 
cells.
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5.2 Purification of recombinant proteins 
Protein purifications were carried out using either affinity chromatography Propond 
purification system or Avidin tag purification system. SDS-PAGE analyses were used 
to characterize purified recombinant enzymes. Purifications were successful with the  
CAIX-C-His and the CAIX-N-His. Protein fractions of the CAIX-C-his and the CAIX-
N-His were additionally extremely pure protein fractions as can be seen in Figures 9a 
and 9b. CAIX-Avd purification was not successful. The produced protein CAIX-Avd 
was found in the resin (black arrow) but not in the eluted fractions Figure 9c. This result 
indicated that the protein was not eluted. Because the purifications were successful with 
other recombinant proteins containing the CA IX catalytic domain, it was decided to 
proceed the studies with CAIX-C-His and CAIX-N-His. The experiments with CAIX-
Avd were not continued. Results of the characterizations are presented in Figures 9a, 9b 
and 9c.  
 
a                                                          b                               c 
Figure 9.  SDS-PAGE gel figures a (CAIX-C-His), b (CAIX-N-His) and c (CAIX-Avd) 
from protein purifications by using coomassie staining.   m=marker F=fraction W= 
wash R= resin 
 
 
5.3 His tag removal after protein purifications 
Recombinant proteins were characterized using SDS-PAGE and Western Blot analyses 
before and after the His tag removal. After the protein purifications, eluted protein 
fractions were pooled and the buffer was exchanged to 50mM Tris-HCl. pH 7.5. The 
protein solution was then treated with thrombin slurry to remove the His tag. The His 
tag removal was successful with CAIX-N-His but not with CAIX-C-His. The protein 
size was clearly smaller after thrombin treatment which indicated a successful His tag 
removal. These SDS-PAGE results are presented in Figure 10. The His tag removal was 
also confirmed using Western Blot analysis. The antibody used in Western Blot was an 
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anti-His antibody, which showed that after thrombin treatment the His tag was 
successfully removed (Figure 11).  
 
 
Figure 10. CAIX-N-His before (bt) and 
after (at) thrombin treatment.  
 
Figure 11. CAIX-N-His before (bt) and 
after (at) thrombin treatment. 
 
5.4 Concentration of final protein preparations 
Concentrations of the recombinant proteins were measured using DCTM Protein Assay 
from Bio-Rad and PierceTM BCA Protein Assay. Protein concentrations of 358  ug/ml 
(CAIX-C-His) and 618 ug/ml (CAIX-N-His) were moderate and sufficient for further 
analyses, but not for the crystallization experiments for 3D structure determination. The 
results of the concentrations are presented in Table 3. The amounts of the protein 
solutions were 900 µl of CAIX-C-His and 930 µl of CAIX-N-His. 
 
Table 3. Concentrations of the recombinant proteins CAIX-C-His and the CAIX-N-His.  
 DC BCA DC + BCA 
Average 
CAIX-C-His 339 ug/ml 370 ug/ml 358 ug/ml 
Average 
CAIX-N-His 707 ug/ml 529 ug/ml 618 ug/ml 
 
5.5 Catalytic activity of the recombinant proteins 
Activity analyses were carried out using an applied photophysics stopped-flow 
instrument in the laboratory of Dr. Claudiu T. Supuran (Bioinorganic Chemistry 
Laboratory, University of Florence, Italy).  Enzyme activities were measured with and 
without 50μM ZnCl2. Activity values were also measured in presence of the ZnCl2, 
because it was unknown if the purified fraction of recombinant protein contained 
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enough Zn2+ to occupy the active sites of enzyme molecules. Results are presented in 
Table 4, which includes also previously published activity values measured with 
catalytic domain of CA IX produced in E.Coli (Wingo, Tu et al. 2001). CAIX-C-His 
showed identical values with the CA IX catalytic domain produced in E.Coli. Full 
length CA + PG form showed similar activity values with CA II that has been 
considered to be the most active CA, according to previous literature (Khalifah 1971).  
Addition of the ZnCl2 into the reaction increased activity values. Catalytic activity 
increased with CAIX-C-his form by tenfold, and with whole length CA + PG form by 
twentyfold in the presence of the ZnCl2. Comparative experiments were also done with 
other CA isozymes, I, II, IV, XII, XIV and CA XV, in the presence of ZnCl2 (Table 5).  
CA XV was produced under the same experimental conditions used for CA IX. CA XV 
did not show same increase in activity values. These results showed that the insect cell 
expression system offered enough Zn2+ ions to the active site of the CA molecules. 
Additionally it indicated that the addition of ZnCl2 did not cause an artificial increase in 
the CO2 hydration (Hilvo, Baranauskiene et al. 2008).   
 
Table 4. Activity values of CAIX: CAIX-C-His, CAIX E Coli and CA+PG form with 
and without 50 μM ZnCl2 (Hilvo, Baranauskiene et al. 2008) 
 
CAIX  
Kcat 
(s-1) 
Km 
(mM) 
kcat/Km 
(M-1S-1) 
CAIX, E Coli 3.8 x 105 6.9 5.5 x 107 
CAIX-C-His, sf9 3.8 x 105 7.0 5.4 x 107 
CAIX-C-His, sf9, ZnCl2 4.2 x 106 7.5 5.6 x 108 
CAIX, CA+PG, sf9 1.1 x 106 7.5 1.5 x 108 
CAIX, CA+PG, sf9, 
ZnCl2 
2.5 x 107 7.3 3.4 x 109 
 
 
Table 5. Effect of 50μM ZnCl2 on the CO2 hydration activity of various CA isozymes 
(Hilvo, Baranauskiene et al. 2008). 
 
Isoenzyme CA activity (%) 
hCA I 73 ± 6 
hCA II 61 ± 4 
hCA IV 63 ± 5 
hCA IX 2266 ± 131 
hCA XII 58 ± 4 
hCA XIV 57 ± 3 
mCA XV 60 ± 5 
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6 Discussion 
CA IX has been analyzed intensively during the last decades, but some of its 
biochemical properties were uncharacterized when this study was conducted. In 
addition, the production of recombinant protein in insect cells was not reported in the 
previous literature for any CA. Thus, the goal of this study was to produce and purify 
recombinant CA IX proteins in insect cells. The aim was to use these CA IX 
recombinant proteins to analyze the activity, inhibition and oligomerisation of CA IX. 
The activity analyses were a part of this study, but the oligomerisation, stability, 
glycosylation, and inhibitory analyses are not reported here as they were conducted on 
separate further analyses (Hilvo, Baranauskiene et al. 2008, Innocenti, Hilvo et al. 
2008).  
 
Another aim was to conduct crystallization experiments to define the 3D structure of 
CA IX. The crystallization of CA IX had been tried in several research groups after 
production in bacterial and mammalian expression systems, but these attempts had 
failed. Therefore, the catalytic domain (CAIX-C-His, CAIX-N-His and CAIX-Avd) and 
PG-domain (CAIX-PG) were produced separately in this study, as the leading 
hypothesis was that the crystallization might be more feasible with several different 
target molecules. The insect cell line used for the production was Sf9, and the used 
expression system was baculovirus expression vector system (BVES). Also the High 
Five cells were planned to be used for the production, but during the time of this study it 
was decided not to use these cells because they did not grow well enough. The use of 
insect cell expression system for the production of recombinant CA proteins was found 
to be a functional way to produce highly pure CA IX enzyme. Later the results of this 
analysis were included in a report published by Hilvo et al (Hilvo, Baranauskiene et al. 
2008).  Hilvo et al used, however, also full length form of CA IX (PG+CA) containing 
both CA IX catalytic domain and CA IX PG-domain. The activity data of PG+CA form 
is also reported in this study. 
 
Purifications of produced recombinant proteins were performed by means of affinity 
chromatography using Probond purification system and Avidin tag purification system. 
Two different purification systems were used in order to find out which one is more 
	   43	  
feasible for CA IX protein. For the separations of the recombinant proteins, Probond 
purification system had an 8 x His tag and Avidin purification system had an Avidin 
tag. The His and the Avidin tags used in this study were aimed to be removed by 
thrombin cleavage. This removal was unsuccessful with C-terminal His tag (CAIX-C-
His) but it was, however, successful with N-terminal His tag (CAIX-N-His). The reason 
why the thrombin cleavage did not work with C-terminal His tag is unclear. It may 
relate to enzyme structure, which may have prevented thrombin from accessing the 
cleavage site. The removal of His tag was not successful, even though long incubation 
times and different enzyme concentrations were tested. Besides the observation that C-
terminal His tag was not removable, it may be concluded that it does not affect the 
catalytic activity of CA IX enzyme, firstly because the activity data was identical 
between CAIX-N-His (without His-tag) and CAIX-C-His enzymes (Hilvo, 
Baranauskiene et al. 2008), and secondly because the activity values were similar with 
the catalytic domain expressed in E.Coli, where the glutathione S-transferase tag was 
successfully removed (Wingo, Tu et al. 2001).  
 
The production of recombinant protein CAIX-Avd was not as successful, and therefore, 
the comparison between the purification systems could not be done. Similarly to CAIX-
Avd, the production of recombinant protein CAIX-PG was not as successful as was 
expected. The amounts of produced CAIX-PG protein were very low and the protein 
remained inside the cell for unexplained reasons. Both of the proteins CAIX-Avd and 
CAIX-PG were detected inside the cell using the Western Blot analysis. CAIX-Avd was 
aimed to be detected inside the cell. The cells were broken by sonication, but even after 
the sonications, the purifications were not successful. It is possible that these proteins 
formed aggregates inside the cell and therefore the secretion did not occur. There are 
several reasons why the produced recombinant protein may form aggregates. 
Heterologous proteins may reach non-physiological concentrations, which may promote 
aggregation. Overexpression of heterologous genes is stressful and may cause the 
saturation of the cellular folding machinery. Rapid intracellular protein accumulation 
may increase the probability of aggregation. Accordingly, the formation of aggregates is 
likely to occur during the production of recombinant proteins. The way of induction 
may also affect the solubility of the recombinant product (Palomares, Estrada-Moncada 
et al. 2004). Amounts of the purified recombinant proteins (CAIX-C-His, CAIX-N-His) 
produced in this study were moderate but suitable for the aimed activity analyses, 
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oligomerisation, stability, glycosylation and inhibitory studies, especially because the 
protein purity was high (Hilvo, Baranauskiene et al. 2008, Innocenti, Hilvo et al. 2008). 
However, due to low amount of purified proteins, the planned structural studies could 
not be conducted (Table 3).  
 
Activity analyses were performed with CAIX-C-His, CA-N-His (data not shown) and 
also with full length PG+CA produced by Hilvo et al (Hilvo, Baranauskiene et al. 
2008). Measured activity values were also compared with previously published results, 
where the catalytic activity of CA IX was measured with recombinant CA protein 
produced in E. Coli (Wingo, Tu et al. 2001). This recombinant CA protein produced in 
E. Coli contained only the catalytic domain of CA IX. Additionally, the catalytic 
activity was measured in the presence of 50 µM ZnCl2. The analyses were performed 
with the presence of ZnCl2, because it was unknown whether the recombinant protein 
produced in insect cells contained enough Zn2+ to saturate the active sites of all enzyme 
molecules. The correlation between the activity of the catalytic domain produced in the 
baculovirus-insect cell and the bacterial expression systems was observed. However, the 
addition of ZnCl2 to the CAIX-C-His enzyme produced in insect cell increased its 
catalytic performance by approximately tenfold. The catalytic activity of PG + CA was 
increased by twentyfold. In fact, the activity values measured with full length PG+CA 
form showed catalytic activity, which was higher than reported in previous literature for 
this enzyme (Wingo, Tu et al. 2001). The PG + CA form showed the same kcat/Km 
value as that measured for CA II without the addition of ZnCl2 or other metal additives 
(Khalifah 1971). This result was very novel because CA II has been considered to be 
the most active CA isozyme (Hilvo, Baranauskiene et al. 2008).  
 
To confirm that the insect cell expression system offered enough Zn2+ ions, comparative 
analyses were also performed with other CA isozyme, CA XV, in the presence of ZnCl2 
(Table 5). CA XV was produced using similar production system and experimental 
conditions. ZnCl2 addition to CA XV inhibited catalytic activity of the enzyme. In 
control experiments with isozymes I, II, IV, XII, and XIV, the addition of ZnCl2 to the 
assay decreased the CO2 hydration activity. These results showed that the insect cell 
expression system offered enough Zn2+ ions for catalysis. Additionally it also indicated 
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that the addition of ZnCl2 did not cause an artificial increase in the CO2 hydration 
(Hilvo, Baranauskiene et al. 2008).  
 
The PG-domain was observed to have a notable influence on enzyme activity of CA IX. 
The difference between the PG + CA and CA forms was that the PG + CA form 
consisted also the PG domain. Because the activity values showed a significant 
difference between the catalytic domain and the full length CA+PG form, it may be 
concluded that the PG domain has an increasing effect in the CO2 hydration activity of 
the CA domain. The mechanism behind that effect remained unexplained. 
 
Before this study was conducted, CA IX was assumed to have a trimeric structure 
(Pastorekova, Zavada 2004). However, the later oligomerisation and stability studies 
made with CA-form (CAIX-C-his) and PG+CA form showed that CA IX probably has 
a dimeric structure that is stabilized by intermolecular disulfide bond(s). This important 
observation was later reported by Hilvo et al (Hilvo, Baranauskiene et al. 2008), and it 
was crucial in finishing the crystallization of CA IX successfully. Indeed, also the later 
crystallization experiments made with catalytic domain of CA IX (mutated Cys-41 to 
Ser) proved the assumption that CA IX is a dimeric protein (Alterio, Hilvo et al. 2009). 
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7 Conclusions 
This study belonged to novel experiments, which proved that the Baculovirus insect cell 
expression system is a functional way to produce CA IX. Also His tag purification 
system was found to be a fuctional way to purify CA IX. Amounts of the purified 
recombinant proteins were relatively low, but they were suitable for the activity studies. 
The planned structural studies could not, however, be made due to low amount of 
purified proteins. According to the results of the activity analyses, the CA IX catalytic 
domain has identical activity values with the catalytic domain produced in E.Coli. 
Comparison of the activity of the CA IX catalytic domain and the full length CA IX 
form (PG+CA) showed that the enzyme with PG domain has remarkably higher activity 
values. Thus, it was concluded that the proteoglycan domain has a notable influence on 
enzyme activity. The addition of ZnCl2 to the enzyme fraction was found to increase the 
catalytic activity. This property was concluded to be a unique feature for CA IX. In fact, 
the catalytic activity of the PG + CA form in the presence of ZnCl2 was higher than 
what was measured before for any other CAs. The results of this study were used in 
further analyses, which revealed for the first time that CA IX has a dimeric structure, 
which is stabilized by intermolecular disulfide bond(s).  
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9 Appendix 1. 
 
CAIX-C-His 
Extras, BglII, optimized signal sequence, CA-domain, thrombin, 8xHIS, STOP, 
HindIII, extras 
 
           Nucleotide sequence 
 
ggccagatctatggctcccctgtgcccctccccctggctgcccctgctgatccccgctcc 
cgctcccggtctgaccgtgcagctgctgctgtccctgctgctgctgatgcccgtgcaccc 
ccagcagagtcattggcgctatggaggcgacccgccctggccccgggtgtccccagcctg 
cgcgggccgcttccagtccccggtggatatccgcccccagctcgccgccttctgcccggc 
cctgcgccccctggaactcctgggcttccagctcccgccgctcccagaactgcgcctgcg 
caacaatggccacagtgtgcaactgaccctgcctcctgggctagagatggctctgggtcc 
cgggcgggagtaccgggctctgcagctgcatctgcactggggggctgcaggtcgtccggg 
ctcggagcacactgtggaaggccaccgtttccctgccgagatccacgtggttcacctcag 
caccgcctttgccagagttgacgaggccttggggcgcccgggaggcctggccgtgttggc 
cgcctttctggaggagggcccggaagaaaacagtgcctatgagcagttgctgtctcgctt 
ggaagaaatcgctgaggaaggctcagagactcaggtcccaggactggacatatctgcact 
cctgccctctgacttcagccgctacttccaatatgaggggtctctgactacaccgccctg 
tgcccagggtgtcatctggactgtgtttaaccagacagtgatgctgagtgctaagcagct 
ccacaccctctctgacaccctgtggggacctggtgactctcggctacagctgaacttccg 
agcgacgcagcctttgaatgggcgagtgattgaggcctccttccctctggtgccccgtgg 
     ttcccaccaccatcaccaccatcaccactaaaagcttggcgaa 
 
           Amino acid sequence 
 
ARSMAPLCPSPWLPLLIPAPAPGLTVQLLLSLLLLMPVHPQSHWRYGGDPPWPRVSPACA 
GRFQSPVDIRPQLAAFCPALRPLELLGFQLPPLPELRLRNNGHSVQLTLPPGLEMALGPG 
REYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTAFARVDEALGRPGGLAVLAA 
FLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFSRYFQYEGSLTTPPCA 
QGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLNGRVIEASFPLVPRGS 
     HHHHHHHHKLGE 
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CAIX-N-His 
 
Extras, BglII, optimized signal sequence, 8xHIS, thrombin, CA-domain, STOP, 
HindIII, extras  
            
           Nucleotide sequence 
 
ggccAGATCTatggctcccctgtgcccctccccctggctgcccctgctgatccccgctcc 
cgctcccggtctgaccgtgcagctgctgctgtccctgctgctgctgatgcccgtgcaccc 
ccagcgtctgcaccaccatcaccaccatcaccacctggtgccccgtggttcccacaggga 
caaagaaggggatgaccagagtcattggcgctatggaggcgacccgccctggccccgggt 
gtccccagcctgcgcgggccgcttccagtccccggtggatatccgcccccagctcgccgc 
cttctgcccggccctgcgccccctggaactcctgggcttccagctcccgccgctcccaga 
actgcgcctgcgcaacaatggccacagtgtgcaactgaccctgcctcctgggctagagat 
ggctctgggtcccgggcgggagtaccgggctctgcagctgcatctgcactggggggctgc 
aggtcgtccgggctcggagcacactgtggaaggccaccgtttccctgccgagatccacgt 
ggttcacctcagcaccgcctttgccagagttgacgaggccttggggcgcccgggaggcct 
ggccgtgttggccgcctttctggaggagggcccggaagaaaacagtgcctatgagcagtt 
gctgtctcgcttggaagaaatcgctgaggaaggctcagagactcaggtcccaggactgga 
catatctgcactcctgccctctgacttcagccgctacttccaatatgaggggtctctgac 
tacaccgccctgtgcccagggtgtcatctggactgtgtttaaccagacagtgatgctgag 
tgctaagcagctccacaccctctctgacaccctgtggggacctggtgactctcggctaca 
gctgaacttccgagcgacgcagcctttgaatgggcgagtgattgaggcctccttctaaaa 
     gcttggcgaa 
 
           Amino acid sequence 
 
ARSMAPLCPSPWLPLLIPAPAPGLTVQLLLSLLLLMPVHPQRLHHHHHHHHLVPRGSHRD 
KEGDDQSHWRYGGDPPWPRVSPACAGRFQSPVDIRPQLAAFCPALRPLELLGFQLPPLPE 
LRLRNNGHSVQLTLPPGLEMALGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHV 
VHLSTAFARVDEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLD 
ISALLPSDFSRYFQYEGSLTTPPCAQGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQ 
     LNFRATQPLNGRVIEASFKLGE 
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CAIX-Avd 
 
Extras, BglII, Avidin signal, Avidin, GGSGGS, thrombin, CA-domain, STOP, 
HindIII, extras 
 
           Nucleotide sequence 
 
ggccagatctatggtgcacgcaacctccccgctgctgctgctgctgctgctcagcctggc 
tctggtggctcccggcctctctgccagaaagtgctcgctgactgggaaatggaccaacga 
tctgggctccaacatgaccatcggggctgtgaacagcagaggtgaattcacaggcaccta 
catcacagccgtaacagccacatcaaatgagatcaaagagtcaccactgcatgggacaca 
aaacaccatcaacaagaggacccagcccacctttggcttcaccgtcaattggaagttttc 
agagtccaccactgtcttcacgggccagtgcttcatagacaggaatgggaaggaggtcct 
gaagaccatgtggctgctgcggtcaagtgttaatgacattggtgatgactggaaagctac 
cagggtcggcatcaacatcttcactcgcctgcgcacacagaaggagggcggttccggtgg 
ctccctggtgccccgtggttcccacagggacaaagaaggggatgaccagagtcattggcg 
ctatggaggcgacccgccctggccccgggtgtccccagcctgcgcgggccgcttccagtc 
cccggtggatatccgcccccagctcgccgccttctgcccggccctgcgccccctggaact 
cctgggcttccagctcccgccgctcccagaactgcgcctgcgcaacaatggccacagtgt 
gcaactgaccctgcctcctgggctagagatggctctgggtcccgggcgggagtaccgggc 
tctgcagctgcatctgcactggggggctgcaggtcgtccgggctcggagcacactgtgga 
aggccaccgtttccctgccgagatccacgtggttcacctcagcaccgcctttgccagagt 
tgacgaggccttggggcgcccgggaggcctggccgtgttggccgcctttctggaggaggg 
cccggaagaaaacagtgcctatgagcagttgctgtctcgcttggaagaaatcgctgagga 
aggctcagagactcaggtcccaggactggacatatctgcactcctgccctctgacttcag 
ccgctacttccaatatgaggggtctctgactacaccgccctgtgcccagggtgtcatctg 
gactgtgtttaaccagacagtgatgctgagtgctaagcagctccacaccctctctgacac 
cctgtggggacctggtgactctcggctacagctgaacttccgagcgacgcagcctttgaa 
     tgggcgagtgattgaggcctccttctaaaagcttggcgaa 
 
           Amino acid sequence 
 
ARSMVHATSPLLLLLLLSLALVAPGLSARKCSLTGKWTNDLGSNMTIGAVNSRGEFTGTY 
ITAVTATSNEIKESPLHGTQNTINKRTQPTFGFTVNWKFSESTTVFTGQCFIDRNGKEVL 
KTMWLLRSSVNDIGDDWKATRVGINIFTRLRTQKEGGSGGSLVPRGSHRDKEGDDQSHWR 
YGGDPPWPRVSPACAGRFQSPVDIRPQLAAFCPALRPLELLGFQLPPLPELRLRNNGHSV 
QLTLPPGLEMALGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTAFARV 
DEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFS 
RYFQYEGSLTTPPCAQGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLN 
     GRVIEASFKLGE 
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CAIX-PG 
 
Extras, BglII, optimized signal sequence, 8xHIS, thrombin, PG-domain, STOP, 
HindIII, extras 
 
           Nucleotide sequence 
 
ggccAGATCTatggctcccctgtgcccctccccctggctgcccctgctgatccccgctcc 
cgctcccggtctgaccgtgcagctgctgctgtccctgctgctgctgatgcccgtgcaccc 
ccagcgtctgcaccaccatcaccaccatcaccacctggtgccccgtggttcccagaggtt 
gccccggatgcaggaggattcccccttgggaggaggctcttctggggaagatgacccact 
gggcgaggaggatctgcccagtgaagaggattcacccagagaggaggatccacccggaga 
ggaggatctacctggagaggaggatctacctggagaggaggatctacctgaagttaagcc 
     taaatcagaagaagagggctccctgaagttagaggatctacctTAAAAGCTT ggcgaa 
 
           Amino acid sequence 
 
ARSMAPLCPSPWLPLLIPAPAPGLTVQLLLSLLLLMPVHPQRLHHHHHHHHLVPRGSQRL 
PRMQEDSPLGGGSSGEDDPLGEEDLPSEEDSPREEDPPGEEDLPGEEDLPGEEDLPEVKP 
     KSEEEGSLKLEDLPKLGE 
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10 Appendix 2. 
 
CAIX-C-His 
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CAIX-N-His 
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